Showing 2941-2950 of 4063 results for "".
- Trefoil Therapeutics Announces TTHX1114 Data Presentations at the ARVO 2023https://modernod.com/news/trefoil-therapeutics-announces-tthx1114-data-presentations-at-the-arvo-2023/2481536/Trefoil Therapeutics announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision
- Grants Available for Students, Residents to Attend Neuro-Optometric Rehabilitation Association 2023 Conferencehttps://modernod.com/news/grants-available-for-students-residents-to-attend-neuro-optometric-rehabilitation-association-2023-conference-2023-conferenc/2481463/The Neuro-Optometric Rehabilitation Association International (NORA) is offering up to 10 students and residents with an interest in neuro-rehabilitation an opportunity to apply for a student grant (
- Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in MGDhttps://modernod.com/news/azura-ophthalmics-presents-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481286/Azura Ophthalmics announced that positive 3-month efficacy and safety results from its
- Conference and Exhibit Hall Registration Now Open for Vision Expo East 2023 Taking Place March 16-19 in New York Cityhttps://modernod.com/news/conference-and-exhibit-hall-registration-now-open-for-vision-expo-east-2023-taking-place-march-16-19-in-new-york-city/2481282/Conference and Exhibit Hall Registration opens today for
- Genentech Launches Phase 2a Study of RG6501 (OpRegen) in Patients With Geographic Atrophyhttps://modernod.com/news/genentech-launches-phase-2a-study-of-rg6501-opregen-in-patients-with-geographic-atrophy/2481274/Lineage Cell Therapeutics announced that its partner Genentech has
- Study: Specialized Smart Soft Contact Lenses Can Address Global Issue of Glaucoma Diagnosis, Managementhttps://modernod.com/news/study-specialized-smart-soft-contact-lenses-can-address-global-issue-of-glaucoma-diagnosis-management/2481144/The vision of
- Santen and UBE Receive FDA Approval for Omlonti for the Reduction of Elevated IOP in Patients with Primary Open-Angle Glaucoma or Ocular Hypertensionhttps://modernod.com/news/santen-and-ube-receive-fda-approval-for-omlonti-for-the-reduction-of-elevated-iop-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension/2481115/Santen and UBE announced that the FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22. Omi
- SAV-IOL to Showcase IOL Technology at ESCRS 2022https://modernod.com/news/sav-iol-to-showcase-new-iol-technology-at-escrs-2022/2481038/After nearly 3 years of virtual congresses and canceled tradeshows worldwide, SAV-IOL announced it will be exhibiting at this year’s ESCRS event in Milan, Italy, September 16-19 at stand B14 at MiCo Convention Centre. SAV-IOL invites all participants to come check out their E
- American Academy of Optometry and American Academy of Optometry Foundation Announces 2022 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-and-american-academy-of-optometry-foundation-announces-2022-award-recipients/2481036/
- NORA Issues Response to Medical Groups' Joint Guidance of Vision Disorders Following a Concussionhttps://modernod.com/news/nora-response-to-medical-groups-joint-guidance-of-vision-disorders-following-a-concussion/2480978/Below is the response from the Neuro Optometric Rehabilitation Association (NORA) regarding the recent statement from various ophthalmic organizations i